Conventional measures of RV function, including echocardiographic indexes, invasive hemodynamic assessments of afterload and compliance, ejection fraction, and RV dimensions and mass, do not distinguish between SSc-PAH and IPAH. 4, [7] [8] [9] However, in 2013, we reported that patients with SSc-PAH have an intrinsic defect in RV chamber contractility compared with patients with IPAH that results in adverse RV-pulmonary artery coupling at rest. 7 In a subsequent study, we showed that patients with SSc-PAH also have depressed RV force-frequency responses and RV contractile reserve with exercise compared with those with IPAH. 8 A consequence of this disparate reserve is that the RV dilates during exercise in patients with SSc-PAH but not those with IPAH. 8 In contrast to systolic measures, diastolic chamber abnormalities, including relaxation and end-diastolic pressure, were similarly altered in both groups.
These studies turned the spotlight from the pulmonary vasculature to the RV as a critical pathophysiological feature of SSc-PAH. Many factors could underlie the contractile differences, although the presence of systolic depression without corresponding relaxation defects in SSc-PAH 7 led us to hypothesize that the sarcomere itself may be prominently involved. The dependence of myofilament force on calcium has been reported in only a few PAH studies, with just 1 study conducted with human tissue, and the results have varied. [10] [11] [12] Pulmonary artery constriction in the rat lowered maximal Ca 2+ -activated tension, 11 whereas this was unaltered in hypoxia-induced PAH induced in calves 10 and was increased in human PAH. 12 The human study examined mostly tissue from patients with PAH from congenital heart disease and did not include any patients with SSc-PAH.
The present study tested the hypothesis that RV sarcomere defects differentiate SSc-PAH from IPAH and predict intact RV contractility and reserve function. Because echo Doppler studies have reported RV defects in patients with SSc without PAH, 13 we also examined myocardium from patients with SSc who presented with exertional dyspnea but no resting PAH (SSc-d). Control heart RV septal tissue was provided from explanted but unused donor hearts. We found a striking depression of RV maximal Ca 2+ -dependent tension in SSc-PAH, directionally opposite to increased tension in IPAH. SSc-d had intermediate abnormalities. Maximal sarcomere tension corresponds with intact RV rest and reserve function measured in the same patients. Thus, defects of the RV sarcomere are a core feature differentiating 2 of the most common forms of PAH and pose a potential therapy target for patients with SSc-PAH and SSc-d.
METHODS

Study Subjects
We prospectively enrolled 24 patients clinically referred for right-sided heart catheterization to evaluate PAH or exercise-induced pulmonary hypertension at the Johns Hopkins Hospital from November 2012 to March 2017. Patients with SSc-PAH and SSc-d were enrolled, as were subjects with IPAH.
Clinical Perspective
What Is New?
• Right ventricular (RV) myofilaments isolated from human subjects with systemic sclerosis (SSc)-associated pulmonary arterial hypertension (PAH) exhibit diminished contractile force and abnormal calcium sensitivity compared with control myofilaments, in contrast to hypercontractile compensation in idiopathic pulmonary arterial hypertension.
• What Are the Clinical Implications?
• Among patients with PAH, those with SSc-PAH suffer disproportionately poor outcomes, even with treatment with standard PAH-directed therapies.
• These findings uncover key deficiencies in the SSc-PAH RV and suggest that therapies targeted at RV myofilament contractile dysfunction may prove particularly useful for this vulnerable PAH subpopulation.
• Furthermore, patients with SSc with only exerciseinduced pulmonary hypertension would appear to make up an at-risk population that may warrant improved screening and treatment paradigms.
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Diagnostic and exclusionary criteria for these groups have been previously described. 8 All patients consented to the procurement of endomyocardial biopsies from the RV septum, obtained under echocardiographic guidance. A subset of patients separately consented to invasive RV pressure-volume (PV) relation analysis, with data measured both at rest and during supine bicycle exercise. Details of the PV methods and intact patient results have been previously reported. 8 Endomyocardial tissue was obtained in 7 patients with IPAH, 11 patients with SSc-PAH, and 6 patients with SSc-d, and all tissue was compared with 7 RV septal samples obtained from age-matched control donor hearts. The protocols were approved by the Johns Hopkins University Institutional Review Board, and informed consent was obtained from all patients. Not all procedures and assays could be performed in each subject ( Table I in the online-only Data Supplement). Donor RV septum was obtained with cold cardioplegia and open chest surgical excision, and tissue was rapidly dissected and frozen. The University of Pennsylvania Institutional Review Board and the Gift-of-Life donor program in Philadelphia, PA, approved the donor tissue protocol, with consent for research use of donated heart tissue obtained from the families of the deceased. The data and study materials will not be available to other researchers as they are sensitive human subjects data.
Study Design
Demographic information and clinical characteristics of the study group were obtained prospectively by pulmonary hypertension specialists using standardized assessments. Sixminute walk tests and other laboratory data were measured either at or within 6 months before right-sided heart catheterization. After routine catheterization study, 3 to 4 endomyocardial biopsies (≈2-3 mg per biopsy) were obtained from the RV septum with a 7F endomyocardial bioptome (Argon Medical, Plano, TX). Each piece was rapidly frozen in liquid nitrogen immediately on removal, with 1 piece first placed in optimal cutting temperature solution before freezing to improve tissue preservation. This piece was used for the myofilament studies. In a subset of patients, another piece was placed in formalin for histopathology. Flash-frozen donor RV septal tissue was shipped by overnight express and analyzed in our laboratory.
Invasive PV assessments at rest and during supine bicycle ergometry were performed as previously described. 8 PV analyses include data from these and additional patients. Data from the additional patients were obtained with the Inca System (Millar, Houston, TX) and CD Leycom PV catheters (RP-CA-41103-PN, Millar) because the previously used catheters were discontinued. 8 All PV data were analyzed with custom WinPVAN software.
Myofilament Function
Myocardium was frozen at −140°C until studied. Methods for force-calcium analysis of biopsy-derived skinned myocytes have been previously reported.
14 Briefly, biopsies were incubated with 0.3% Triton X-100 in isolation buffer with protease inhibitors (Sigma-Aldrich, St. Louis, MO) and phosphatase inhibitors (PhosSTOP, Roche Applied Science, Penzberg, Germany) and then homogenized by low-speed pulverization to generate a skinned cellular preparation.
After washing in isolation buffer, myocytes were affixed to a force transducer-length controller (Aurora Scientific, Aurora, Canada) with ultraviolet-activated adhesive (Norland Products, Cranbury, NJ) ( Figure I ] required to achieve 50% maximal force, micromoles), and cooperativity (Hill) coefficient (h). In a subset of myocytes, we exposed cells to the active catalytic subunit of protein kinase A (PKA; 0.125 U/mL, 20 min; Sigma-Aldrich) and repeated measurements of the F-Ca 2+ dependence.
Histology
Heart biopsies fixed in 10% formalin were embedded in paraffin, and 10-µm sections were cut and stained with Masson Trichrome. Histology was analyzed by investigators blinded to group using an Aperio Imagescope (Leica Biosystems, Nussloch, Germany), and percent fibrosis was determined by calculating the total area of blue-hued staining as a percentage of total area. Standardized settings (hue, 0.66; threshold, 0.33) were used to define positive fibrosis staining.
Statistical Analysis
Data are presented as mean±SD in the tables and text and mean±SEM in figures unless otherwise indicated. Parametric tests were used when possible; nonparametric tests were used when normality criteria were not met. Fibrosis, as defined by an excess of 2.5% of the biopsy area, was compared between groups with the Fisher exact and Kruskal-Wallis ANOVA. Passive tension at each SL was compared between groups with 1-way ANOVA with post hoc testing using the Tukey test. For cell mechanics studies, 2 to 3 myocytes were tested from each biopsy (majority was 3 per biopsy), yielding a total of 68 myocytes. 
RESULTS
Study Population
Demographic and clinical data for each patient group are provided in Table II in the online-only Data Supplement. The groups were matched in nearly all parameters, with somewhat fewer female control subjects and somewhat greater body surface area in subjects with IPAH. Clinical and cardiac magnetic resonance-based features of subjects with IPAH and SSc-PAH studied in the current cohort were very similar to those previously reported. 7, 8 Resting RV contractility, as assessed by ventricular end-systolic elastance (Ees), and RV-pulmonary arterial coupling, as assessed by the ratio of Ees to arterial elastance, were both lower in subjects with SSc-PAH compared with those with IPAH (Table) . Subjects with SSc-d had significantly lower right atrial and pulmonary artery pressures and pulmonary afterload (resistance and ratio of Ees to arterial elastance) compared with subjects with SSc-PAH and IPAH, and their Ees and ratio of Ees to arterial elastance were similar to those in subjects with IPAH (Table) . Measures of in vivo diastolic function (time constant of relaxation and peak flow rate normalized to end-diastolic volume) were similar between groups. When available, the hemodynamic response to exercise is also provided in the Figure 1A and 1B). Tis- Data are presented as mean±SD. Comparisons between groups were made with the Wilcoxon rank-sum test. CO indicates cardiac output; Ea, effective arterial elastance; Ees, end-systolic elastance; Ees/Ea, right ventricle-pulmonary artery coupling ratio; IPAH, idiopathic pulmonary arterial hypertension; mPAP, mean pulmonary artery pressure; PADP, pulmonary artery diastolic pressure; PASP, pulmonary artery systolic pressure; PAWP, pulmonary artery wedge pressure; PFR/EDV, peak flow rate normalized to end-diastolic volume; PVR, pulmonary vascular resistance; RAP, right atrial pressure; SSc-d, systemic sclerosis without resting pulmonary arterial hypertension; SSc-PAH, systemic sclerosis-associated pulmonary arterial hypertension; TPR, total pulmonary resistance; τ(Suga), relaxation time constant; and Vo 2 , oxygen consumption.
*P value comparing IPAH and SSc-PAH. †P value comparing SSc-PAH and SSc-d.
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sue stiffness could not be assessed from the biopsy, but assessment of isolated myocyte stiffness was possible. Myocytes were stiffer compared with both forms of PAH versus controls (P<0.05 from SLs of 2.2-2.6 μm), but this increase was virtually identical between SSc-PAH and IPAH (P>0.75 from SLs of 2.2-2.6 μm; Figure 1C ).
Maximal Tension and Calcium Sensitivity Differ Between SSc-PAH, IPAH, and SSc
Unlike passive myocyte stiffness, active F-Ca 2+ dependence was found to have marked differences between the PAH groups, each being different from control subjects (Figure 2A Figure 2B ). Figure 2C Trichrome as a percentage of total biopsy area was increased in patients with SSc-PAH vs IPAH or SSc with exertional dyspnea but no resting PAH (SSc-d) based on a threshold of 2.5% fibrosis. C, Passive tension as a function of escalating sarcomere length was measured in IPAH, SSc-PAH, and nonfailing control myocytes (n=5 subjects per group). Passive tension between all 3 groups was compared with 1-way ANOVA at each sarcomere length. *Post hoc P<0.05 between control subjects and patients with IPAH. †Post hoc P<0.05 between control subjects and patients with SSc-PAH.
parameters were similar to those of control subjects. Summary Hill equation parameters for all groups are provided in Figure 2D . Myocyte cross-sectional area is also shown and was similar among the 4 groups (Figure 2D) . Human myocyte resting length in our experimental setup was generally 1.70 to 1.80 μm. A, Force-calcium data were obtained in nonfailing control, IPAH, and SSc-associated pulmonary arterial hypertension (PAH) myocytes to obtain maximal calcium-activated tension (F max ) and calcium sensitivity (EC 50 ) (n=7 subjects per group). B, Data were normalized to maximal tension to illustrate shifts in calcium sensitivity (measured as EC 50 or the calcium concentration necessary for 50% maximal activation). C, Myofilament force-calcium data of control subjects, patients with SSc-PAH, and those with SSc free of PAH (SSc-d). D, F max , EC 50 , Hill coefficient (h), and myocyte cross-sectional area (CSA) data; data presented as mean±SD. F max was increased in patients with IPAH vs control subjects, whereas it was decreased in patients with SSc-PAH vs both control subjects and patients with IPAH. In patients with SSc-d, F max was intermediate between control subjects and patients with SSc-PAH. EC 50 was decreased in patients with SSc-PAH vs control subjects, patients with IPAH, and those with SSc-d. There was no significant difference between groups in Hill coefficient or myocyte CSA. *Significant difference in post hoc comparison.
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PKA Exposure Equalizes Calcium Sensitivity Among Patient Groups
In both left ventricular and RV failure, increased Ca 2+ sensitivity (reduced EC 50 ) has been reported and linked to depressed PKA phosphorylation of myofilament proteins, notably of troponin I (TnI). 10, 17, 18 Only patients with SSc-PAH displayed this, and we hypothesized that this also might reflect depressed PKA activation. Myocytes from both PAH groups and control subjects were therefore further exposed to the catalytically active PKA subunit, and data before and after exposure were compared. In patients with IPAH and control subjects, PKA increased EC 50 slightly (P<0.05 versus non-PKA); however, this rise was significantly greater in SSc-PAH myocytes, resulting in near-identical EC 50 values after PKA exposure (P=0.002 for interaction between PAH group and PKA treatment; Figure 3A and 3B). 19 and reduced titin phosphorylation has been implicated as a mechanism of increased passive myocyte stiffness in the RV of patients with PAH. 12, 18 We therefore assessed the impact of PKA in both PAH groups by change in passive tension at a fixed SL of 2.1 μm. This similarly declined after PKA in both PAH groups but was unchanged in control subjects (P<0.05 for both; Figure 3C ).
F max Predicts RV Rest Contractility and Exercise-Reserve Response
To test whether the lower F max in SSc-PAH, partial decline in SSc-d, and rise in IPAH correlated with in vivo RV systolic function, we regressed F max and resting chamber contractility (Ees), the latter derived from invasive RV PV analysis in the same patients. Figure 4A shows these variables directly correlated (R 2 =0.46, P=0.002). We also tested whether F max correlated with RV exercise performance. As previously reported, 8 RV contractile reserve (change in Ees) is depressed in subjects with SSc-PAH. This was associated with chamber dilation (higher RV end-diastolic volumes) at submaximal exercise, whereas patients with IPAH showed no dilation at the same exercise level (stage 2, 25 W). 
DISCUSSION
The present study reveals that patients with SSc-PAH have depressed sarcomeric function manifested prominently by a substantial decline in maximal force-calcium dependence. The exact opposite, an increase in this dependence, is observed in IPAH. This disparity parallels and predicts corresponding differences in global RV chamber systolic function at rest and on exertional demand. Because the latter has been found to correlate with clinical outcome, the new results surprisingly focus the spotlight on the RV sarcomere rather than pulmonary vasculature in explaining differences in SSc-PAH and IPAH. This is further strengthened by the finding that patients with SSc-d who do not yet have resting PAH also exhibit abnormal sarcomere function. Although previous efforts to treat both SSc-PAH and IPAH have focused on pulmonary load, our results suggest that tailored treatment focusing on RV sarcomeric disease maybe particularly useful for SSc-PAH.
To the best of our knowledge, only 1 previous study, by Rain and colleagues, 12 has reported human RV forcecalcium relations in PAH. In this report, the authors found that myocytes were passively stiffer, much as we observed. From their F-Ca 2+ data, they found that F max was ≈40% above that in nonfailing controls and EC 50 was slightly lower. This study examined primarily tissue from PAH patients with congenital heart disease; only 3 of 11 had IPAH and none had SSc-PAH. Congenital heart disease involves complex mechanical loads and chronic disease history, so comparisons with the current IPAH and SSc-PAH groups are difficult. The previous study was also based on tissue obtained at time of heart-lung transplantation, so all patients had endstage disease. 12 The present results are the first to include both SSc-PAH and SSc-d and to perform analyses from heart biopsies reflecting an earlier disease stage. Our findings in IPAH are similar to those of Rain et al, 12 suggesting that this form of PAH retains RV sarcomere compensation even at late stages.
In any form of heart disease involving marked increases in chamber load, the net result depends on the interaction between load severity and the myocardium. Because pulmonary arterial load was similar in both PAH groups, unique RV features linked to SSc would appear to be more important for the specific maladaptive response and disease severity. Whether patients with SSc without any abnormal pulmonary vascular load have similar sarcomere defects remains unknown because these patients are not referred for right-sided heart catheterization or biopsy. However, noninvasive echo Doppler data from such patients have found subclinical systolic and diastolic defects based on strainbased measurements. 13 The intermediate defect in SScd may indicate that even intermittent PAH as induced during exercise is sufficient to manifest a sarcomere defect. Although the underlying cause remains unknown, SSc-related immune activation with vasculopathy and inflammation could be factors leading to damaged myofibrillar proteins. A, Myofilaments from a subset of control subjects, patients with idiopathic pulmonary arterial hypertension (IPAH), and patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) (3 subjects per group) were directly incubated with PKA. B, Baseline calcium sensitivity (EC 50 ) in all 3 groups mirrored trends of the larger cohort. With PKA, there was a slight increase in EC 50 in control subjects and patients with IPAH. On the other hand, PKA completely markedly increased EC 50 in the SSc-PAH group to control levels. Change in EC 50 was significantly greater in patients with SSc-PAH than in both control subjects and patients with IPAH (disease×group interaction, P=0.002). C, PKA treatment led to a decrease in passive tension, at a sarcomere length of 2.1 μm, in both patients with IPAH and those with SSc-PAH, but no change in control subjects. There was no significant difference in PKA-mediated passive tension change between patients with IPAH and SSc-PAH. *P<0.05; post hoc P value applied when applicable.
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The EC 50 is actively regulated by posttranslational changes in regulatory thin filament proteins, including TnI, troponin C, troponin T, myosin binding protein C, myosin light chain, and tropomyosin. 20 It is controlled by multiple kinases, including phosphorylation by PKA, 17 protein kinase G, 21 protein kinase C, 22 protein kinase D, 23 and AMP-activated protein kinase 24 (particularly targeting TnI and troponin T), and by oxidation, 25 nitrosylation, and acetylation. 26 Many of these factors lead to Ca 2+ desensitization (increase EC 50 ), although some (eg, TnI phosphorylation by AMP-activated protein kinase and protein kinase Cβ2) result in sensitization. EC 50 often declines with left ventricular failure, and this has been attributed to reduced TnI phosphorylation by PKA caused by downregulation of β-adrenergic signaling because PKA activation restores it to control levels. 17 Such sensitization may in part compensate for depressed calcium transients in heart failure, but it may also worsen diastolic dysfunction. 27 Evidence that RV PKA deficiency occurs with PAH has been reported. 10, 12, 18 We found evidence for PKA deficiency in active force-Ca 2+ dependency in SSc-PAH, as observed in forms of left ventricular failure. This suggests another component of abnormal systolic reserve in these patients compared with patients with IPAH, perhaps related to greater inhibition of sympathetic stimulation. This remains to be tested in vivo. PKA effects on passive myocyte stiffness were similar between groups, although our capacity to detect differences may have been limited by having restricted the analysis to an SL of 2.1 μm, for which stiffness differences are slight.
Unlike EC 50 or passive stiffness, F max is not modified by PKA, and indeed, most kinases that alter sarcomere function leave F max intact. Previous studies have found that F max is depressed by proteolysis of regulatory thin filament proteins and perturbations in structural sarcomere integrity. 28 For example, F max declines after ischemic injury in conjunction with troponin I proteolysis by calpain-1 at the C-terminus. 29, 30 Mice expressing a mutant TnI with this truncation exhibit a depressed F max and develop heart failure. 31 Another protein that can undergo destructive proteolysis is myosin binding protein C, and in this case, the cleaved byproduct serves as a poison peptide to depress F max . 32 F max also declines with oxidative stress, 33 and in a canine tachypacing heart failure model, reduced F max was correlated with structural disruption of the sarcomere with reduced force generation by ≈40% of myofibrils. 34 At present, we do not know what modifies F max in SSc-PAH and to a smaller extent in SSc-d, but the hope is that ongoing studies in additional patients will reveal factors to further guide precision therapy. However, even without a specific molecular explanation for the F max defect in SSc-PAH, its presence and correlation to intact RV physiology suggest that small-molecule inotropes designed to enhance sarcomere function 20 may be particularly useful.
We previously described that the RV contractile response to faster heart rates (force-frequency response) and calcium cycling also was predicted to be diminished in SSc-PAH compared with IPAH. 8 However, because calcium transients could not be measured in vivo, we were unable to test whether these defects were caused by calcium transient disparities or abnormal sarcomere responses to calcium. The F max and EC 50 disparities between IPAH and SSc-PAH shown here would be adequate to explain force-frequency response differences as well, because the force-frequency response depends on levels of stimulating Ca 2+ . This was shown in a study using a calcium sensitizer that modifies F max but not Ca 2+ cycling to improve the force-frequency response. Thus, improving sarcomere dysfunction in SSc-PAH should also help frequency-dependent systolic reserve.
Diastolic stiffening of PAH RV myocytes has been described, 12, 18 and our results are concordant with such data. Chamber stiffness combines properties of myocytes, the interstitium, and extrinsic factors (eg, RV-left ventricular interaction, pericardium). In this regard, our in vivo analysis has not revealed significant disparities between IPAH and SSc-PAH. Although SSc-PAH had more endocardial fibrosis, this could be consistent with an autopsy study that found SSc fibrosis to be disproportionately reflected in the endocardium and interventricular septum. 36 In contrast, we found that T2-weighted cardiac magnetic resonance imaging analysis of fibrosis was similar between IPAH and SSc-PAH. 8 Myocyte stiffness is also similarly increased in both diseases, supporting the net results in intact patients. Thus, although subtle differences may still exist, it is unlikely that diastolic properties are a primary contributor to worsened RV function or clinical course in SSc-PAH.
This study has several limitations. Given its invasive nature, endomyocardial biopsies from healthy controls could not be obtained. The RV septal tissue from nonfailing donor hearts can be affected by patient history, anesthesia, neurohormonal activation, and other conditions at the time of organ procurement. We did not assess the RV free wall given the higher risk of myocardial perforation, but previous studies suggest homogeneity of myofilament function from multiple anatomic sites within a given RV. 10 Although the individual sample sizes (number of hearts) were relatively small for each group, we analyzed many cells, which confer their own variability given the extraction procedure. Our analysis was adjusted for the random effects of multiple measurements per biopsy piece. Our ability to correlate the individual results to the same subject's intact heart data strengthens the conclusions.
CONCLUSIONS
We demonstrate that in contrast to the hypercontractile response of IPAH myofilaments, RV myofilaments from SSc-PAH exhibit a marked decrease in maximal calcium-activated force and an abnormal increase in calcium sensitivity. These findings are strengthened by their correlation to measures of in vivo RV contractility and reserve. Abnormalities in calcium sensitivity, but not maximal calcium-activated tension, were restored by PKA. The presence of intermediate defects in SScd further supports a primary influence of SSc on the RV. Together, these data highlight the critical role of RV sarcomere dysfunction in SSc-PAH and suggest that the SSc-PAH RV is characterized by a phenotype of RV failure, not compensation. Targeted therapies to enhance RV myofilament function in this PAH subgroup, with more vigilant surveillance and perhaps early intervention in patients with borderline SSc, should be explored.
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